Aurealis Therapeutics Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support and Accelerated Assessment of AUP-16 in Non-healing Diabetic Foot Ulcers
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach […]
Interview with Haritha Samaranayake CMO of Aurealis Therapeutics | Professional journey, AUP-16 clinical trials in DFU & development plans for oncology
Watch full interview on YouTube What was the journey that took Haritha Samaranayake to his current role as CMO? What are the current advances in the clinical trials of Diabetic Foot Ulcers? How can the Aurealis technology be leveraged for cancer treatment? We discussed this and more in the interview with Haritha so let’s get […]
